

Intensive Amplitude-specific Therapeutic Approaches for Parkinson's Disease

Toward a Neuroplasticity-principled Rehabilitation Model

**Becky G. Farley, PT, PhD; Cynthia M. Fox, PhD, CCC-SLP;
Lorraine O. Ramig, PhD, CCC-SLP; David H. McFarland, PhD, SLP**

Recent scientific advances in animal models of Parkinson disease suggest exercise is a legitimate disease-modifying therapeutic option that contributes to behavioral recovery and neurochemical sparing. These data challenge current rehabilitative assumptions and emphasize the need for neuroplasticity-principled exercise-based approaches to challenge the impaired system. We suggest one novel solution—the intensive practice of amplitude—a global motor control parameter. Training a single focus (amplitude) across (1) disciplines (physical, occupational, speech therapy), (2) tasks (transfers, activities of daily living, recreation), and (3) motor systems (speech, locomotion, reaching) may provide the complexity, difficulty, and repetition necessary for disease-modification in human Parkinson disease. **Key words:** *amplitude, cross-system effects, cueing, exercise, motor training, neuroplasticity, rehabilitation, recovery*

From the Department of Physiology, AHSC, University of Arizona, Tucson (Dr Farley); National Center for Voice and Speech, Denver, Colo, and Department of Neurology, University of Arizona, Tucson (Dr Fox); Department of Speech, Language, Hearing Sciences, University of Colorado-Boulder; National Center for Voice and Speech, Denver Center for the Performing Arts, Denver, Colo; and Columbia University, New York City, New York (Dr Ramig); École d'orthophonie et d'audiologie et centre de recherche en sciences neurologiques, Faculté de médecine, Université de Montréal and School of Communication Sciences and Disorders and Center for Research on Language, Mind and the Brain, McGill University (Dr McFarland).

This work was supported, in part, by funding from National Institute of Health Grant R21 NS043711 and R01 DC-01150. Special thanks to Gail Kosblum for comments on the manuscript; Michelle Prior, Heather Spellman, and Kristan Leech for technical contributions; and to the subjects who participated in these studies.

Corresponding author: Becky G. Farley, PT, PhD, Department of Physiology, AHSC, University of Arizona, Tucson, AZ 85724 (e-mail: bfarley@u.arizona.edu).

ADVANCES in neuroscience reveal that exercise acts at the molecular level to inhibit cell death, increase synaptic efficiency, and promote behavioral recovery in animal models (rodents) of Parkinson's disease (PD).^{1,2} Furthermore, research has identified fundamental principles of exercise that contribute to neuroplasticity in animal models of PD and in humans with stroke-related hemiparesis and spinal cord injury.^{1,3-8} These data challenge the assumptions of current rehabilitative models that there is no potential for neuroplasticity or recovery in people with PD; therefore, current therapies primarily target compensatory behavioral interventions that bypass basal ganglia (BG) pathology.⁹⁻¹⁵

Instead, we propose to translate these data from animal models of PD and human stroke-related hemiparesis and spinal cord injury to a neuroplasticity-principled model of rehabilitation for the treatment of human PD. We will provide the theoretical foundation

for exercise-based programs that are immediately available at the time of early diagnosis, continuous, and that challenge the impaired system to optimize the potential for disease modification in PD. Toward that goal, we will introduce intensive amplitude-specific exercise-based therapeutic approaches that adhere to the principles of neuroplasticity, as one possible solution to improve rehabilitation outcomes for people with PD.

This article will introduce the reader to the science and practice motivating intensive amplitude-specific therapeutic approaches. Specifically, we will discuss (1) why exercise is a legitimate therapeutic option for PD, (2) how to integrate the principles of neuroplasticity into mode of delivery of treatment, and (3) why training-increased amplitude as a single, overriding treatment focus can encourage cross-motor system improvements and optimize function. We will also provide data to support the successful application of the fundamentals of an amplitude-based speech therapy (LSVT/LOUD) to the limb motor system (LSVT/BIG)*; and to the limb combined simultaneously with the speech motor system (LSVT/BIG and LOUD).

THE SIGNIFICANT NEED

PD is the second most common neurodegenerative disease, after Alzheimer's disease.¹⁶ With a mean age of diagnosis at 62 years, approximately 1.6% of the people 65 years and older suffer from PD,¹⁷ and incidence and prevalence increase with age. At the time of diagnosis, neuronal death in the substantia nigra has already exceeded a critical threshold (ie, ~70%–80% loss).^{18,19} At this time, drug therapies are able to mask many of the motor symptoms. Over time, however, the effect of drugs deteriorates and motor and psychiatric side effects develop. Neurosurgical techniques such as

deep brain stimulation may be employed at this point, especially for those people who develop medication side effects of involuntary movements (dyskinesias). Deep brain stimulation effectively reduces many motor symptoms allowing patients to reduce their level of medication temporarily and thereby reducing side effects and improving motor function.^{20,21} Despite medical and surgical management, most of the 1.5 million Americans with PD have significant speech and movement deficits that negatively impact their quality of life.^{22,23} Affected individuals become disabled or retire early, are forced to give up activities they enjoy, incur substantial medical costs, and have increased mortality.^{23–25} On the basis of 2004 estimates, PD costs the United States 34 billion annually in direct health-related expenses, disability-related costs, and lost productivity.^{25,26} As the number of elderly older than 65 years increases, the prevalence of PD is predicted to grow 4-fold by 2040,²⁷ and these costs are expected to exceed 50 billion dollars.²⁸ Even a 10% slowing of progression of PD could increase the chances that individuals could maintain an improved, productive quality of life, despite living out the rest of their life with a chronic disease, and result in a significant annual savings to healthcare costs.

For the 60,000 individuals diagnosed annually with PD, therapeutic options that modify (slow, halt, or reverse) disease progression are needed regardless of the mechanism. Multiple-disease mechanisms have been shown to be involved in the cascade of events leading up to the death of dopamine (DA) cells associated with PD, including mitochondrial dysfunction, oxidative stress, excitotoxicity, and inflammation.²⁹ Several classes of exogenous agents have been shown in vitro and in vivo to be capable of disease modification by interfering with many of these potential disease mechanisms.³⁰ The most promising agents include pharmaceuticals and supplements^{20,31} and use of gene or cell therapy to increase the availability of DA or neurotrophic factors locally.^{32–34} To date, none of these treatments have yet been shown

*Patent pending for LSVT/BIG; LSVT/BIG and LOUD-GleeCo, LLC.

to slow, halt, or reverse disease progression in human PD and attention has recently turned to exercise as a potential therapeutic agent.

EXERCISE IS A LEGITIMATE DISEASE-MODIFYING THERAPEUTIC OPTION IN PD

The use of exercise as a physiologic tool to promote the body's own endogenous brain repair mechanisms is a virtually untapped resource for people with PD. Research in the area of exercise neurobiology has shown that exercise may interfere with multiple mechanisms involved in cell death, stimulate the proliferation of new neurons,^{35,36} alter metabolic and immune system responses,³⁷⁻³⁹ increase blood supply,⁴⁰ and protect against the "erosive neural events of aging, neurodegeneration, and brain injury."^{1,41-43} Many of these neurobiological processes are triggered by the direct effect of exercise on increasing the endogenous expression of neurotrophic factors.⁴⁴⁻⁴⁸ Because PD is a disease of aging, it is promising that exercise research with aged animal models has linked many of these same brain repair mechanisms to improved cognitive function in aged humans,^{47,49,50} suggesting that they may also contribute to behavioral recovery in the case of disease or injury.

In animal models of PD, daily exercise (environmental enrichment, forced limb use, treadmill training) has been shown to reverse motor deficits, attenuate the loss of DA, and modulate genes and proteins important to BG function.^{41,43,51} This behavioral recovery and neuroplasticity has been directly related to elevated levels of striatal glial-derived neurotrophic factor (GDNF) that promotes survival of DA neurons.^{44,46} Even more recently, exercise has been shown to induce the generation of GDNF-producing cells (glia) in the substantia nigra where DA cells live.⁵² Accordingly, it is reasonable to hypothesize that exercise in human PD promotes plasticity in the DA system through mechanisms of trophic support, with a likely candidate being the endogenous release of GDNF.² Support-

ive data in human studies suggest that people with PD have low levels of GDNF,⁵³ and that a history of exercise in early life may reduce risk for PD.^{54,55}

The timing of exercise intervention is critical to determining which brain repair mechanisms will be induced and where in the central nervous system they will be located. For example, in animal models of PD, exercise may be prophylactic (preventative) and capable of protecting DA neurons from toxic events, but the degree of protection is dependent on baseline fitness levels and how early exercise is started.^{41,42} After diagnosis of PD (injury), a continuous maintenance threshold of exercise may be required to provide the trophic support necessary to maintain the growth and survival in the remaining viable DA neurons.^{1,41,43} In contrast, inactivity and failure to engage damaged systems (impairment-related or self-imposed) may be prodegenerative contributing to further degradation of function⁴¹ and a downregulation of endogenous neurotrophic factors.^{1,56,57} In more advanced disease (longer duration), exercise has been shown to produce molecular changes within the damaged BG pathways, but progressively higher intensity, velocity, longer duration practice, and task-specific paradigms may be required.⁵¹

Altogether, these data suggest that multiple time-dependent mechanisms are capable of contributing to behavioral recovery in PD. They suggest a need for exercise interventions in human PD that are available at diagnosis, promote continuous exercise, and avoid inactivity. It is unknown how these data will translate to human PD because of the difference in acute animal models of PD versus the chronic DA neuronal death in human PD.⁵⁸⁻⁶⁰ Despite these caveats, these data are so compelling that they have led basic science researchers to suggest that early physical training interventions may actually halt the bilateral progression of the disease.^{1,2,42-44} It is time to partner with these basic scientists, translate these data to human clinical trials, and integrate them into a new era of clinical

practice for people with PD. We will first explore more traditional rehabilitative models for PD and then propose an alternative neuroplasticity-principled approach.

CURRENT REHABILITATION PARADIGMS

People with PD are rarely seen by a physical or occupational therapist until they begin to experience disability and impaired function, usually because of loss of balance. By this time, what started out as a primary motor impairment of bradykinesia or hypokinesia has advanced to secondary complications and general deconditioning, perhaps exaggerated by progressive inactivity. The goal of rehabilitation has been to enable motor function as long as possible for using (1) general exercise programs customized to address the list of problems in people with PD including exercises for cardiovascular fitness, strength, range of motion, posture, gait, coordination, and balance as a group,⁶¹⁻⁶⁶ home-based,⁶⁷⁻⁷⁰ or individualized,⁷¹⁻⁷⁵ or (2) specialized behavioral strategies to teach patients compensations. For example, external cues (auditory, visual, tactile) are used to elicit larger steps, faster walking speeds, decrease freezing of gait, improve posture and rotation, and overcome freezing.^{9,12,13,76-87} Another strategy is to use instructional techniques that teach patients to avoid difficult tasks by (1) modifying the task (avoid dual tasks, divide complex sequential movement into chunks of simpler movements) and (2) restructuring the environment (avoid clutter, narrow walkways). Patients are also instructed to use attentional mechanisms to replace automaticity with focused attention on key aspects of movement. This may involve techniques that emphasize attention to size, video feedback, mental imagery, rehearsal, or breathing and relaxation.^{82,88-92}

These specialized behavioral strategies may enhance the duration of treatment effects when combined with traditional problem-based exercise approaches.^{9,78} When combined with task-specific over ground gait train-

ing (1 day/~328 feet) they have been shown to improve gait performance (2 hours⁸²), but more intensive training (10 days/~1800 feet/day) may be necessary for retention (4 weeks⁸⁰). No studies, however, have demonstrated generalization of these techniques (ie, carryover to “untrained” tasks or contexts).

To integrate the use of these behavioral strategies into clinical practice, guidelines are needed for clinical decision making about task and patient selection, modality (auditory, visual, attentional), parameters to use for correction (frequency, step size), and dosage. Consequently, the RESCUE project has recently developed 15 evidence-based guidelines with video examples, methods, and patient handouts to provide clinicians with the needed practical tools to implement standardized cueing training (www.rescueproject.org). The use of 3 of these external cueing techniques for gait training in a home setting has recently been tested in a multicentered randomized crossover trial¹² (see also reference 93).

A NEUROPLASTICITY-PRINCIPLED MODEL

Traditional approaches that are problem-based or that focus on teaching compensations imply that neurophysiologic changes are no longer possible (ie, that it is too late for people with PD to retrain “lost” motor control). Thus, the approaches are typically not based on physiologic hypotheses to directly counteract disease-specific pathophysiology (ie, impaired internally cued amplitude regulation) or principles of motor learning. Exceptions include a few studies that have incorporated high-intensity and/or progressive exercise protocols for task-specific strengthening,^{71,94} postural stability,⁹⁵ over ground walking,⁸⁰ and treadmill training.⁹⁶⁻⁹⁸ However, these approaches are seldom used in clinical settings. Instead, therapists target the management of multiple symptoms incorporating multiple therapeutic compensatory strategies for improving gait, balance,

posture, transfers, self-care, and leisure. As a result, the therapeutic intensity is low to moderate, and both the therapists' and the patient's efforts may become diffused.

This diffusion of focus and minimal therapeutic intensity may partially explain the lack of robust and lasting benefits in previous published systematic evidenced-based reviews for physical therapy.⁹⁹⁻¹⁰² To date, no one approach has been identified as superior in a comparative trial.¹⁰² This is not due to the lack of approaches, as almost every type of general exercise approach (group or individual) has been investigated at least once, as well as task-specific training (treadmill, balance, aerobic, strength, flexibility), or "cued" exercise programs.⁹⁹⁻¹⁰² Despite methodological challenges and differences among these randomized controlled studies, dosage intensity (frequency or duration) was relatively similar (ie, 2-4 times per week for 4-10 weeks) and would satisfy sports physiology requirements for athletes of at least 2 to 3 times per week for approximately 6 weeks to achieve training effects.¹⁰³ On the other hand, other exercise parameters that affect therapeutic intensity (ie, complexity, difficulty, repetition) were not typically documented or controlled and may be critical to achieving the most robust and sustained treatment effects.

The systematic manipulation of these essential exercise parameters in animal studies suggests that "what you do matters" and may determine the nature of plasticity that occurs. For example, these studies have shown that repetition alone (for reaching, locomotion, strengthening tasks) does not produce brain reorganization of the cortical maps representing the practicing limb.¹⁰⁴⁻¹⁰⁶ Instead, tasks that are difficult (small-well pellet retrieval) require new skill acquisition or that are complex (acrobatic training) are essential to driving the changes in morphology that reorganize cortical maps (ie, increased dendrites, synapse number).¹⁰⁷⁻¹⁰⁹ Other studies suggest that repetition may be necessary to induce sustained changes in activation (neuronal or network) that transfer and carry over outside the therapeutic environment.^{105,110}

This is supported by transcranial stimulation studies in humans showing that stimulation trains of 1800 pulses, but not 150 pulses, were sufficient to induce lasting changes in corticospinal excitability.¹¹¹ Altogether, these data suggest that there may be no one superior approach, as long as a critical threshold of high effort (complexity, difficulty) exists over an adequate period of time (repetition). This is supported in animal models of PD, showing that 3 very different approaches were capable of inducing neurochemical sparing and behavioral recovery. These approaches included exploration of a novel new environment, forced use of a limb during everyday activities, or general whole-body progressive locomotion training.^{41-43,46,51,52} One could infer from the aforementioned studies, that an adequate combination of complexity, difficulty, and repetition was present across each of the interventions to have produced these changes.

Specificity of exercise provides another way to increase therapeutic intensity. Studies in humans with stroke-related hemiparesis and spinal cord injury have shown that it is through the activation and use of the impaired limbs in patterns of movement that emphasize "relearning" normal patterns of use that drive changes in or around those parts of the central nervous system that are damaged.^{4,112} The translation of these data to people with PD would suggest that task-specific approaches should focus directly on trying to reverse the impairments (ie, bradykinesia or hypokinesia) by engaging the patient to retrain bigger and faster movements for everyday movement. However, task-specific studies to date have been problem-based or they trained compensatory strategies by using external or attentional cues.^{79,80,95} Preliminary clinical trials in human PD suggest that repetitive task-specific approaches may be tolerated by patients.^{71,79,80,94,95} result in longer retention,^{80,97,98} and produce task-specific changes in the brain.^{79,96} However, it is unknown how well training with one cue on one task will transfer to other tasks or motor systems. If generalization is

limited, the requirement of therapist and patient time may prove to be monumental to address improvement in multiple functional tasks for different motor systems. We propose here a novel approach to maximize therapeutic intensity in people with PD through the manipulation of complexity, difficulty, repetition, and to increase generalization through a single amplitude-specific focus.

ONE SOLUTION: INTENSIVE AMPLITUDE-SPECIFIC TRAINING

We hypothesize that amplitude-specific training is “task-specific” for people with PD,¹¹³ thereby targeting the proposed pathophysiologic mechanisms underlying bradykinesia or hypokinesia—inadequate muscle activation.^{114–116} Because of DA loss, this impairment emerges as a result of faulty processing of kinesthetic feedback, motor output, and context feedback within the BG. This faulty sensorimotor processing leads to a reduced gain in the motor command for selecting and reinforcing movement amplitude.^{114,117–119} This hypothesis is supported by single cell recording studies¹²⁰ and brain activation imaging studies.^{113,117,121} Therefore, rather than trying to bypass BG pathology in therapy, we hypothesize that retraining “normal amplitude use” may enhance activation of damaged BG pathways and slow or halt their degradation.^{1,113} This amplitude-specific approach is further supported by animal and human models of stroke-related hemiparesis that have used “forced-use” paradigms to improve function of the impaired limb and promote greater movement-associated activation in the remaining cortex of the injured hemisphere and in remote interconnected regions.^{122–124} We predict that by incorporating intensity into an amplitude-specific training approach for people with PD, we will be able to similarly target the repetitive activation of the damaged system across multiple interconnected motor regions involved in “relearning” normal amplitude use. Therefore, intensive amplitude-specific training may give rise

to distributed effects across “untrained” tasks or systems.¹²⁵

In addition to targeting BG pathology, the amplitude-specific therapeutic approaches to be discussed here are delivered in a standardized manner and adhere to the fundamental treatment principles of a speech therapy intervention for people with PD (LSVT/LOUD). Over 15 years of efficacy, data have established that intensive, high effort, amplitude training taught with self-monitoring of vocal loudness results in significant long-term improvements (out to 2 years) in loudness and speech intelligibility,¹²⁶ and a transfer of improvements across motor symptoms (articulation, swallow, facial expression).^{22,126–128} Preliminary imaging results with positron emission tomography have documented the first neural changes (ie, neural plasticity) following an intensive rehabilitation treatment of any kind for people with PD.^{129,130} Specifically, changes represented a shift from abnormal cortical motor activation pre-LSVT to more normal subcortical organization of speech-motor output post-LSVT.

We have recently developed 2 derivative treatments from the fundamental principles of LSVT/LOUD. These include a physical or occupational therapy approach (LSVT/BIG) and a hybrid physical or occupation therapy combined with speech therapy approach (LSVT/BIG and LOUD). The use of a standardized approach ensures that all subjects get the adequate dosage, delivered in the same manner, as has been shown to be effective in clinical trials. The single focus on amplitude reduces the cognitive load for patients and allows for the simple and redundant practice of amplitude. The intensity is acquired through dosage, repetition, high effort or difficulty, and complexity. The approach is described below for LSVT/BIG.

For example, patients complete multiple repetitions (minimum 12) of 12 daily maximal whole-body bigness tasks. This repetitive practice of amplitude is performed with high intensity and effort. Thus, it is delivered face-to-face at a treatment dosage of 4 days a week for 4 weeks (1-hour sessions). Therapists push

patients to perform at a patient-perceived effort level of 8 or more (scale 1–10, with 10 being the most) on every repetition. To increase carryover to real-world context, the intensive or high effort and repetitive practice becomes progressively more difficult (ie, longer sequences), and complex (ie, dual tasks) over the course of 4 weeks. Starting day 1, patients are required to transfer their “bigness effort” established in the daily maximal tasks to emotionally salient hierarchical tasks, chosen by the subject (ie, getting out of bed, walking to the mailbox, golfing).

The goal of LSVT/BIG is to teach patients a new way of moving in everyday life so that everyday movements provide continuous exercise. To achieve this carryover and maintenance, it is necessary to address the sensorimotor mismatch that accompanies the production of larger, normal amplitude movements—as normal amplitude movements “feel” too BIG.^{131–134} Multiple studies have documented impairments in kinesthesia^{132,133,135–137} that may result from abnormal higher order processing of afferent information.¹³⁸ By directly addressing this sensory mismatch, patients may become “recalibrated” such that by the end of 1 month, they learn to recognize the effort required to internally regulate normal amplitude movements.

IMPACT OF LSVT/BIG ON LIMB MOTOR SYSTEM IN PD

Preliminary results on a subset of data from an RCT have been published and presented as abstracts^{139,140} In that study, we compared LSVT/BIG (BIG, $n = 18$) to an age-matched untreated PD control group (PDC, $n = 11$). Eligible subjects were Hoehn and Yahr stages I–III. All testers were blinded and testing was “uncued” to speed or bigness. The standardized protocol for the LSVT/BIG intervention was delivered 4 days/week for 4 weeks, as described in the previous section and further illustrated in Table 1. Pre- and posttest revealed significant improvements in both trained tasks (trunk rotation and stride length)

and untrained tasks (gait and reaching velocity) in the short term. The improvements in preferred walking (12% velocity, 9% stride length) and functional axial rotation were still different from baseline at a 3-month follow-up ($P \leq .01$, Wilcoxon rank sum test).^{139,140} Interestingly, after intervention, subjects were able to maintain their new improved preferred walking velocity and stride length when challenged with a dual task (walk and say days of week backward), even outperforming an age-matched elderly control group ($P = .01$, Mann-Whitney U test).¹⁴⁰ These improvements in bradykinesia or hypokinesia also generalized to significant clinical improvements on the activities-balance-confidence scale and in quality of life using the summary score from the PD Questionnaire (PDQ-39) (both $P \leq .01$).¹⁴⁰

To determine whether improvements were equivalent across levels of disease severity, change scores for subjects were grouped and graphed according to their Hoehn and Yahr category. Subjects with milder impairment (Stage I) tended to make more improvement than other subjects with moderate impairment (stages II and III). This trend was strongest for the change in gait velocity ($P = .004$, see Fig 2b in Farley and Koshland).¹³⁹ A similar finding for subjects with milder impairment or shorter disease duration has been reported in the literature with a general exercise approach (3/week for 4 months).⁷³ Future studies will need to determine whether training capacity is truly limited in subjects with moderate impairment or whether patients are unable to access their new skills spontaneously and/or require longer duration training.

These data suggest that mildly involved subjects with PD have the potential for bigger and faster movements, yet, they do not use that capacity to make normal amplitude or velocity movements in everyday situations. This pattern of early “nonuse” is especially relevant as recent research in animal models of PD have shown that inactivity may actually contribute to degeneration⁴² and that continuous practice and forced use of

Table 1. An example of how a neuroplasticity-principled rehabilitation model can be used to guide the integration of basic science research to disease-specific therapeutic rationale and interventions*.[†]

Timing matters ^{41, 43, 46, 152, 153}		
<i>Principle</i>	<i>Deficit specific to PD</i>	<i>LSVT/BIG and LOUD</i>
Early exercise has the potential to: rescue DA neurons, prevent chronic disuse, promote system-wide plasticity, and halt disease progression—particularly to the asymptomatic side.	People with early PD have subtle physical under activity (small movements/soft voice). This may be coupled with a lack of awareness or self-correction, leading to further inactivity.	Train people with early PD before function is compromised. Train strategies to raise awareness/avoid neglect and increase muscle activation for normal big/loud. Train whole body—not just impaired side.
Complexity matters ^{154–158}		
<i>Principle</i>	<i>Deficit specific to PD</i>	<i>LSVT/BIG and LOUD</i>
Complex movements or environmental enrichment have been shown to promote greater structural plasticity and synaptic efficacy in adjacent and remote interconnected regions than simple movements	As basal ganglia pathology progresses complex, adaptive, everyday movements are reduced. This loss in automaticity requires conscious attention to task—interfering with dual task performance.	Train complexity of movement with single patient focus (amplitude) to multiple, motor tasks. Retrain automaticity of amplitude in everyday movements progressing complexity by varying contexts, adding dual cognitive/motor loads, and sequential tasks.
Intensity matters ^{51, 96, 159, 160}		
<i>Principle</i>	<i>Deficit specific to PD</i>	<i>LSVT/BIG and LOUD</i>
Intensive practice is important for maximal, sustained plasticity. Intensity can be increased via frequency/duration, reps, difficulty (effort/accuracy), and complexity	Intensive, high effort training can be difficult in PD due to sensory deficits, force control, fatigue, depression, and progressive loss of cardiac sympathetic innervation	Train intensively 1-hour/day, 4 days/week, for 4 weeks; manipulate reps (12 or more); resistance (weight), amplitude effort, duration, accuracy (within healthy range), establish daily homework/carryover exercises. Recalibrate effort required for normal amplitude
Intensity for amplitude increases activation of basal ganglia circuitry and induces synaptic plasticity in striatum		
Use it or lose it/ use it and improve it ^{1, 42, 153}		
<i>Principle</i>	<i>Deficit specific to PD</i>	<i>LSVT/BIG and LOUD</i>
Spared, but compromised DA neurons highly vulnerable to bouts of inactivity/activity. Inactivity may accelerate deficits.	Deficits are subtle—not “red flag” to seek physical/speech therapy. Getting early PD to recognize need for exercise and then convincing them to continually exercise is challenging.	Recruit and target people with early PD, educate them on subtle deficits, and improve motor function that directly impacts real life
Postexercise intervention, there may be a minimum use required to maintain positive effects	Decreased physical activity may be a catalyst in degenerative process	Retrain a new way of speaking and moving in everyday life—normal activity offers continuous exercise

(continues)

Table 1. An example of how a neuroplasticity-principled rehabilitation model can be used to guide the integration of basic science research to disease-specific therapeutic rationale and interventions*.[†] (*Continued*)

Sailency matters ^{22,129,161–163}		
<i>Principle</i>	<i>Deficit specific to PD</i>	<i>LSVT/BIG and LOUD</i>
Practicing rewarding tasks (success/emotionally salient) activates basal ganglia circuitry Rewards are associated with phasic modulation of DA levels critical to induction of striatal plasticity and learning/relearning in PD	People with early PD may experience lack of awareness of subtle motor deficits, depression, loss of motivation and a feeling of “helplessness” Thus, they do not feel they need or would not benefit from exercise/therapy	We retrain salient whole-body familiar movements (core patterns) promoting success. We provide homework tasks that reinforce success of Big and Loud in emotional social interactions. We provide extensive positive feedback

*DA indicates dopamine; PD, Parkinson’s disease.
[†] Six key principles of neural plasticity in column 1 and their relationship to proposed pathophysiologic deficits in PD are described in column 2. The corresponding rationale and possible therapeutic solutions as they pertain to LSVT/BIG and LOUD are described in column 3.

impaired limbs prevent and/or reverse motor impairments.^{41–43,51} These types of data provide further justification for exercise as a legitimate therapeutic option immediately upon *diagnosis*—when there is the most potential for blocking the bilateral progression of the disease and improving motor function on the already-impaired side through multiple mechanisms of plasticity.

Results from the complete RCT using an intention-to-treat analysis to compare (LSVT/BIG to traditional physical therapy [TRAD]) are in preparation and confirm these preliminary data (described for LSVT/BIG vs PDC above). To match dosage (frequency or duration), both treatment groups (LSVT/BIG and TRAD) met according to the standardized protocol for LSVT/BIG (4/week for 4 weeks). In this case, both groups improved, but the changes in LSVT/BIG are consistently more robust and sustained. Because dosage (frequency or duration) was controlled across interventions, these data suggest that an amplitude-specific approach may produce more significant changes than a TRAD general exercise approach (even when delivered at the same dosage). However, subjects in LSVT/BIG were required to work at high effort (8 or more of self-perceived effort) continuously during the daily interventions.

To determine whether amplitude has a specific effect, future comparative studies should match for both dosage *and* effort.

IMPACT OF LSVT/BIG AND LOUD ON LIMB AND SPEECH MOTOR SYSTEMS IN PD

This work has been extended to the development of a novel combined treatment program that *simultaneously* targets speech and limb motor disorders in people with early PD (LSVT/BIG and LOUD).^{141–143} The program, and how it is integrated with the principles of neuroplasticity and PD-specific pathophysiology, is detailed in Table 1. Our hypothesis is that amplitude-specific exercises delivered simultaneously to these apparently diverse motor systems will be complementary and result in enhanced function in targeted behaviors (system-specific effects). The idea that a combined therapeutic approach may be complementary is supported by recent experiments with patients with stroke-related hemiparesis. Specifically, transcranial direct current stimulation of the motor cortex combined with motor training results in enhanced recovery and greater morphological plasticity as compared with motor training alone in these

patients.^{144,145} Similar studies have not been completed in patients with PD.¹⁴⁶ We propose that LSVT/BIG and LOUD may be analogous to a paired motor training paradigm such that increased activation required for greater amplitude for one task (louder speech) may induce an increase in excitability of common circuitry that is further enhanced by the addition of another amplitude task (bigger whole-body movements).^{123,124}

This approach was recently applied to 11 people with early PD (9 stage I, 3 de novo; 2 stage II). Results revealed that all subjects significantly increased vocal sound pressure levels (SPL) (loudness) during sustained vowels and reading (an average of 8–10 db SPL at 30-cm distance from the microphone) and increased stride length (12 cm on the average) and velocity (14 cm/s on the average) during preferred walking.^{141–143} The gains in vocal loudness and gait were comparable to previously published data from earlier studies that targeted speech or limb movements independently.^{139,147,148} These system-specific changes in speech and gait function were accompanied by (1) a 28% decrease in disease severity as revealed by the motor score for the Unified Parkinson's Disease Rating Scale and (2) a 27% improvement in quality of life as revealed by the PDQ-39 summary score.^{141–143} A 30% improvement in the Unified Parkinson's Disease Rating Scale is considered clinically significant and would be evidence for disease modification in studies investigating putative neuroprotective agents.¹⁴⁹ These preliminary data are extremely encouraging and merit additional experimental attention.

In addition to system-specific training effects, we hypothesize that LSVT/BIG and LOUD will result in enhanced function that spreads to behaviors that are *not* specifically targeted by the therapeutic regime.¹²⁵ If improvements are seen, this may indicate that there are distributed effects on motor function that may emerge from the common treatment focus of increased amplitude of movement. For this, we assessed performance on an untrained fine motor

task (handwriting) in a subset of the subjects who received the combined LSVT/BIG and LOUD treatment as compared with an untreated PDC group. Using a pen on a digitizer pad, subjects were instructed to write consecutive cursive “lll”s in their everyday way inside rectangular boxes of various heights (1.0, 1.5, 2.0, 3.0, and 5.0 cm). A between-group comparison of velocity change scores revealed that after intervention, the LSVT/BIG and LOUD group significantly increased velocity for target sizes 1.5, 2.0, and 3 cm by decreasing movement duration while maintaining segment size constant ($P = .02$; unpaired t test).¹⁵⁰

Certainly, these data are preliminary and future studies are needed to determine whether the combined treatment maximizes these cross-system effects or whether they may also be observed when individually treating speech and/or limb movement amplitude. It could be predicted, for example, that the added complexity, attention, and engagement of the simultaneous treatment task “drive” greater improvements in function when contrasted with these behaviors targeted individually. Altogether, these data indicate that an intensive combined therapeutic exercise approach that *simultaneously* targets increased amplitude for speech and whole-body movements is complementary and may result in treatment effects both within and beyond targeted systems. In this manner, the training of a global motor control parameter may potentiate plasticity across brain networks involved in amplitude regulation.^{113,117,121,151} Focusing the enhanced activation on the impaired BG pathways may provide one solution to triggering the body's own endogenous brain repair mechanisms and thereby may interfere with disease progression.

SUMMARY

We have documented that standardized intensive speech and limb treatments focusing on amplitude are effective rehabilitative tools, the results of which can give us insight about the neural mechanisms of disordered motor

control in individuals with PD. The impact of training a single global motor control parameter is powerful in its ability to have maximum functional impact while increasing clinical efficiency. Continued research will further evaluate the distributed effects of LSVT/LOUD, LSVT/BIG, and LSVT/BIG and LOUD across multiple motor systems (speech, reaching, dexterity, balance, articulation, facial expression, swallowing, respiration) to more clearly discern cross-system interactions. We will also continue to systematically investigate the im-

pact of intensive amplitude-based therapies across disease severity and in young and older onset PD in longitudinal studies. To translate the research from animal models of PD to human PD, we propose to use brain imaging techniques to examine the effect of exercise in early PD on restoring function to compromised BG circuits. These data would provide the justification for a delayed-start randomized clinical trial to test the use of exercise as a legitimate disease-modifying therapeutic option immediately upon *diagnosis*.

REFERENCES

1. Kleim J, Jones T, Schallert T. Motor enrichment and the induction of plasticity before or after brain injury. *Neurochem Res*. 2006;11:1757-1769.
2. Smith AD, Zigmond MJ. Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. *Exp Neurol*. 2003;184:31-39.
3. Behrman AL, Bowdren MG, Nair PM. Neuroplasticity after spinal cord injury and training: an emerging paradigm shift in rehabilitation and walking recovery. *Phys Ther*. 2006;86:1406-1425.
4. Fisher B, Sullivan KJ. Activity-dependent factors affecting poststroke functional outcomes. *Top Stroke Rehabil*. 2001;8(3):31-44.
5. Liepert J, Bauder H, Wolfgang HR, Miltner WH, Taub E, Weiller C. Treatment-induced cortical reorganization after stroke in humans. *Stroke*. 2000;31:1210-1216.
6. Shepherd RB. Exercise and training to optimize functional motor performance in stroke: driving neural reorganization? *Neural Plasticity*. 2001;8(1/2):121-129.
7. Vaynman S, Gomez-Pinilla F. License to run: exercise impacts functional plasticity in the intact and injured central nervous system by using neurotrophins. *Neurorehabil Neural Repair*. 2005;19:283-229.
8. Wolpaw JR, Tennissen AM. Activity-dependent spinal cord plasticity in health and disease. *Annu Rev Neurosci*. 2001;24:807-843.
9. Marchese R, Diverio M, Zucchi F, Lentino C, Abbruzzese G. The role of sensory cues in the rehabilitation of parkinsonian patients: a comparison of two physical therapy protocols. *Mov Disord*. 2000;15(5):879-883.
10. Morris ME. Movement disorders in people with Parkinson disease: a model for physical therapy. *Phys Ther*. 2000;80:578-597.
11. Morris ME. Locomotor training in people with Parkinson disease. *Phys Ther*. 2006;86(10):1426-1435.
12. Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE-trial. *J Neurol Neurosurg Psychiatry*. 2006;22 doi: 10.1136/jnnp.2006.097923 (Epub ahead of print).
13. Rubinstein TC, Giladi N, Hausdorff JM. The power of cueing to circumvent dopamine deficits: a review of physical therapy treatment of gait disturbances in Parkinson's disease. *Mov Disord*. 2002;17(6):1148-1160.
14. Schenkman M, Donovan J, Tsubota J, Kluss M, Stebbins P, Butler RB. Management of individuals with Parkinson's disease: rationale and case studies. *Phys Ther*. 1989;69:944-955.
15. Turnbull GI, Millar J. A proactive physical management model of Parkinson's disease. *Top Ger Rehabil*. 2006;22(2):162-171.
16. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. *N Engl J Med*. 2003;348(14):1356-1364.
17. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 1997;62(1):10-15.
18. Lang AE, Lozano AM. Parkinson's disease. First of two parts. *N Engl J Med*. 1998;339(15):1044-1053.
19. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain*. 1991;114:2283-2301.
20. Goetz CG, Werner P, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's Disease: 2001 to 2004. *Mov Disord*. 2005;20(5):523-539.
21. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. *Mov Disord*. 2006;21(suppl 14):S290-S304.

22. Fox C, Morrison C, Ramig L, Sapir S. Current perspectives on the Lee Silverman Voice Treatment (LSVT). *Am J Speech Lang Pathol*. 2002;11:111-123.
23. Schenkman M, Zhu CW, Cutson TM, Whetten-Goldstein K. Longitudinal evaluation of economic and physical impact of Parkinson's disease. *Parkinsonism Relat Disord*. 2001;2:41-50.
24. D'Amelio M, Ragonese P, Morgante L, et al. Long-term survival of Parkinson's disease, a population-based study. *J Neurol*. 2006;253:33-37.
25. Noyes K, Lui H, Li H, Holloway R, Dick AW. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. *Mov Disord*. 2006;3:362-372.
26. Whetten-Goldstein K, Sloan F, Kulad E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. *J Am Geriatr Soc*. 1997;45:844-849.
27. Lilienfeld DE, Perl DP. Projected neurodegenerative disease mortality in the United States, 1990-2040. *Neuroepidemiology*. 1993;12:219-228.
28. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. *Mov Disord*. 2005;20:1449-1454.
29. Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. *Mov Disord*. 2005;20(S11):S3-S10.
30. Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. *J Am Soc Exp Neuro Therapeut*. 2004;1:139-154.
31. Ravina BM, Fagan SC, Hart RG, Hovinga CA, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. *Neurology*. 2003;60:1234-1240.
32. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. *Neurology*. 2003;60:69-73.
33. Gill SS, Patel NK, O'Sullivan K, et al. Intrapatent putaminal administration of glial-derived neurotrophic factor in the treatment of advanced Parkinson's disease. *Neurol*. 2002;58(suppl 3):A241.
34. McKay BS, Goodman B, Falk T, Sherman SJ. Retinal pigment epithelial cell transplantation could provide trophic support in Parkinson's disease: results from an in vitro model system. *Exp Neurol*. 2006;201(1):234-243.
35. Van Praag H, Shubert T, Zhao C, Gage F. Exercise enhances learning and hippocampal neurogenesis in aged mice. *J Neurosci*. 2005;25(38):8680-8685.
36. Kempermann G, Kuhn HG, Gage FH. Experience-induced neurogenesis in the senescent dentate gyrus. *J Neurosci*. 1998;18:3206-3212.
37. Cadet P, Zhu W, Mantione K, Rymer M, Dardik I, Reisman S, Hagberg S, Stefano GB. Cyclic exercise induces anti-inflammatory signal molecule increases in the plasma of Parkinson's patients. *Int J Mol Med*. 2003;12:485-492.
38. Dishman RK, Warren JM, Hong S, et al. Treadmill exercise training blunts suppression of splenic natural killer cell cytotoxicity after footshock. *J Appl Physiol*. 2000;88:2176-2180.
39. Vaynman S, Ying Z, Wu A, Gomez-Pinilla F. Coupling energy metabolism with a mechanism to support brain-derived neurotrophic factor-mediated synaptic plasticity. *J Neurosci*. 2006;139:1221-1234.
40. Kleim JA, Cooper NR, VandenBerg PM. Exercise induces angiogenesis but does not alter movement representations within rat motor cortex. *Brain Res*. 2002;934:1-6.
41. Tillerson J, Cohen A, Philhower J, Miller G, Zigmond M, Schallert T. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. *J Neurosci*. 2001;21(12):4427-4435.
42. Tillerson J, Cohen A, Caudle M, Zigmond M, Schallert T, Miller G. Forced nonuse in unilateral parkinsonian rats exacerbates injury. *J Neurosci*. 2002;22(15):6790-6799.
43. Tillerson JL, Caudle WM, Revere ME, Miller GW. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. *J Neurosci*. 2003;119:899-911.
44. Cohen AD, Tillerson JL, Smith AD, Schallert T, Zigmond MJ. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. *J Neurochem*. 2003;85:299-305.
45. Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. *Trends Neurosci*. 2002;25(6):295-301.
46. Faherty CJ, Shepherd KR, Herasimtschuk A, Smeyne. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. *Mol Brain Res*. 2005;134:170-179.
47. Vaynman S, Gomez-Pinilla F. License to run: exercise impacts functional plasticity in the intact and injured central nervous system by using neurotrophins. *Neurorehabil Neural Repair*. 2005;19:283-229.
48. Ying Z, Roy RR, Edgerton R, Gomez-Pinilla F. Exercise restores levels of neurotrophins and synaptic plasticity following spinal cord injury. *Exp Neurol*. 2005;193(2):411-419.
49. Kirkwood TB. Molecular gerontology. *J Inherit Metab Dis*. 2002;25:189-196.
50. Rogers RI, Meyer JS, Mortel KF. After reaching retirement age physical activity sustains cerebral perfusion and cognition. *J Am Geriatr Soc*. 1990;38:123-128.
51. Fisher B, Petzinger G, Nixon K, et al. Exercise-induced behavioral recovery and neuroplasticity

- in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. *J Neurosci Res*. 2004;77:378-390.
52. Steiner B, Winter C, Hosman K, et al. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease. *Exp Neurol*. 2006;199:291-300.
 53. Chauhan NB, Siegel GJ, Lee LM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. *J Chem Neuroanat*. 2001;21:277-288.
 54. Chen H, Ahang SM, Schwarzschild MA, Hernan MA, Ascherio A. Physical activity and the risk of Parkinson disease. *Neurology*. 2005;64:664-669.
 55. Saso AJ, Paffenbarger RS, Gendre I, Wind AL. The role of physical exercise in the occurrence of Parkinson's disease. *Arch Neurol*. 1992;49(4):360-365.
 56. Neeper SA, Gomez-Pinilla F, Choi J, Cotman C. Exercise and brain neurotrophins. *Nature*. 1995;373:109.
 57. Schinder AF, Poo M. The neurotrophin hypothesis for synaptic plasticity. *Trends Neurosci*. 2000;23:639-645.
 58. Dishman RK, Berthoud HR, Booth FW, et al. Neurobiology of exercise. *Obesity*. 2006;14(3):345-356.
 59. Bezaud E, Gross C. Compensatory mechanisms in experimental and human Parkinsonism: towards a dynamic approach. *Progr Neurobiol*. 1998;55:93-116.
 60. Poulton NP, Muir, GD. Treadmill training ameliorates dopamine loss but not behavioral deficits in hemi-Parkinsonian rats. *Exp Neurol*. 2005;193:181-197.
 61. Bridgewater KJ, Sharpe MH. Trunk muscle training and early Parkinson's disease. *Physiother Theory Pract*. 1997;13:139-153.
 62. Ellis T, de Goede CJ, Feldman RG, Wolters EC, Kwakkel G, Wagenaar RC. Efficacy of a physical therapy program in patients with Parkinson's disease: a randomized controlled trial. *Arch Phys Med Rehabil*. 2005;86:626-632.
 63. Palmer SS, Mortimer JA, Webster DD, Bistevis R, Dickinson GL. Exercise therapy for Parkinson's disease. *Arch Phys Med Rehabil*. 1986;67:741-745.
 64. de Paula FR, Teixeira-Salmela LF, de Moraes Faria CD, de Brito PR, Cardoso E. Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson's disease. *Mov Disord*. 2006;21(8):1073-1077.
 65. Pedersen SW, Oberg B, Insulander A, Vretman M. Group training in Parkinsonism: quantitative measurements of treatment. *Scand J Rehab Med*. 1990;22:207-211.
 66. Schmidtz-Hubtz T, Pyfer D, Kietwein K, Fimmers R, Klockgether T, Wullner U. Qigong exercise for the symptoms of Parkinson's disease: a randomized, controlled pilot study. *Mov Disord*. 2006;21(4):543-548.
 67. Banks MA, Caird FI. Physiotherapy benefits patients with Parkinson's disease. *Clin Rehabil*. 1989;3:11-16.
 68. Caglar AT, Gurses HN, Mutluay FK, Kiziltan G. Effects of home exercises on motor performance in patients with Parkinson's disease. *Clin Rehabil*. 2005;19:870-877.
 69. Hurwitz A. The benefit of a home exercise regimen for ambulatory Parkinson's disease patients. *J Neurosci Nurs*. 1989;21:180-184.
 70. Lun V, Pullan N, Lavelle N, Adams C, Suchowersky O. Comparison of the effects of a self-supervised home exercise program with a physiotherapist-supervised exercise program on the motor symptoms of Parkinson's disease. *Mov Disord*. 2005;20(8):971-975.
 71. Hirsch MA, Toole T, Maitland CG, Rider RA. The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson's disease. *Arch Phys Med Rehabil*. 2003;84:1109-1117.
 72. Comella CL, Stebbins GT, Brown-Toms N, Goetz CG. Physical therapy and Parkinson's disease: a controlled clinical trial. *Neurology*. 1994;44:376-378.
 73. Formisano R, Pratesi L, Modarelli FT, Bonifati V, Meco G. Rehabilitation and Parkinson's disease. *Scand J Rehab Med*. 1992;24:157-160.
 74. Patti F, Reggio A, Micoletti F, Sellaroli T, Deinite G, Nicoletti F. Effects of rehabilitation therapy on Parkinsonians' disability and functional independence. *J Neuro Rehab*. 1996;10:223-231.
 75. Schenkman M, Cutson T, Kuchibhatla M, et al. Exercise to improve spinal flexibility and function for people with Parkinson's disease: a randomized, controlled trial. *J Am Geriatr Soc*. 1998;46:1207-1217.
 76. Bagley S, Kelly B, Tunnicliffe N, Turnbull GI, Walker JM. The effect of visual cues on the gait of independently mobile Parkinson's disease patients. *Physiotherapy*. 1991;77:415-420.
 77. Behrman AL, Teitelbaum P, Cauraugh JH. Verbal instructional sets to normalize the temporal and spatial gait variables in Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 1998;65:580-582.
 78. Dam M, Tonin P, Casson S, Bracco F, Piron L, Pizzolato G, Battistin L. Effects of conventional and sensory-enhanced physiotherapy on disability of Parkinson's disease patients. *Adv Neurol*. 1996;69:551-555.
 79. del Olmo MF, Arias P, Furio MC, Pozo MA, Cudeiro J. Evaluation of the effect of training using auditory stimulation of rhythmic movement in Parkinsonian patients: A combined motor and [F]-FDG PET study. *Parkinsonism Relat Disord*. 2006;12:155-164.
 80. Lehman DA, Toole T, Lofald D, Hirsch MA. Training with verbal instructional cues results in near-term improvement of gait in people with Parkinson disease. *J Neurol Phys Ther*. 2005;29(1):2-8.

81. McIntosh GC, Brown SH, Rice RR, Thaut MH. Rhythmic auditory-motor facilitation of gait patterns in patients with Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 1997;62:22-26.
82. Morris ME, Iansek R, Matyas TA, Summers JJ. Stride length regulation in Parkinson's disease: normalization strategies and underlying mechanisms. *Brain*. 1996;119:551-568.
83. Morris ME, Iansek R. Gait disorders in Parkinson's disease: a framework for physical therapy practice. *Neurol Rep*. 1997;21(4):125-131.
84. Pacchetti C, Mancini F, Aglieri R, Fundaro C, Martignoni E, Nappi G. Active music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation. *Psychosom Med*. 2000;62:386-393.
85. Sideway B, Anderson J, Danielson G, Martin L, Smith G. Effects of long-term gait training using cues in an individual with Parkinson disease. *Phys Ther*. 2006;86(2):186-194.
86. Suteerawattananon M, Morris GS, Etnyre BR, Jankovic J, Protas EJ. Effects of visual and auditory cues on gait in individuals with Parkinson's disease. *J Neurol Sci*. 2004;219:63-69.
87. Thaut MJ, McIntosh GC, Rice RR, Miller RA, Rathbun J, Brault JM. Rhythmic auditory stimulation in gait training for Parkinson's disease patients. *Mov Disord*. 1996;11(2):193-200.
88. Macht M, Ellgring H. Behavioral analysis of the freezing phenomenon in Parkinson's disease: a case study. *J Behav Ther Exp Psychiatry*. 1999;30:241-247.
89. Mohr B, Muller V, Mattes R, et al. Behavioral treatment of Parkinson's disease leads to improvement of motor skills and to tremor reduction. *Behav Ther*. 1996;27:235-255.
90. Muller V, Mohr B, Rosin R, Pulvermuller F, Muller F, Birbaumer N. Short-term effects of behavioral treatment on movement initiation and postural control in Parkinson's disease: a controlled clinical study. *Mov Disord*. 1997;12:306-314.
91. Stallibrass C, Sissons P, Chalmers C. Randomized controlled trial of the Alexander technique for idiopathic Parkinson's disease. *Clin Rehabil*. 2002;16:695-708.
92. Yekutieli MP. A clinical trial of the re-education of movement in patients with Parkinson's disease. *Clin Rehabil*. 1991;5:207-214.
93. Nieuwboer A, Rochester L, Jones J. Cueing gait and gait-related mobility in patients with Parkinson's disease: developing a therapeutic method based on the ICE *Topics Geriatr Rehab*. 2008;24(2):151-165.
94. Dibble LE, Hale TE, Marcus RL, Droge J, Gerber JP, LaStayo PC. High-intensity resistance training amplifies muscle hypertrophy and functional gains in persons with Parkinson's disease. *Mov Disord*. 2006;21(9):1444-1452.
95. Jobges M, Heuschkel G, Pretzel C, Illhardt C, Renner C, Hummelsheim. Repetitive training of compensatory steps: a therapeutic approach for postural instability in Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2004;75:1682-1687.
96. Fisher BE, Allan WD, Salem GJ, et al. The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson's disease. *Arch Phys Med Rehabil*. In press.
97. Pohl M, Rockstroh G, Ruckriem S, Mrass G, Mehrholz J. Immediate effects of speed-dependent treadmill training on gait parameters in early Parkinson's disease. *Arch Phys Med Rehabil*. 2003;84:1760-1766.
98. Miyai I, Fujimoto Y, Yamamoto H, et al. Long-term effect of body weight-supported treadmill training in Parkinson's disease: a randomized controlled trial. *Arch Phys Med Rehabil*. 2002;83:1370-1373.
99. Deane KHO, Ellis-Hill C, Jones D, et al. Systematic review of paramedical therapies for Parkinson's disease. *Mov Disord*. 2002;17(5):984-991.
100. Deane KHO, Jones D, Playford ED, BenShlomo Y, Clarke CE. Physiotherapy versus placebo or no intervention in Parkinson's disease (Cochrane Review). In: *The Cochrane Library*, Issue 2. Oxford: Update Software, 2002.
101. Gage H, Storey L. Rehabilitation for Parkinson's disease: a systematic review of available evidence. *Clin Rehabil*. 2004;18:463-482.
102. Deane KHO, Jones D, Ellis-Hill C, Clarke CE, Playford ED, BenShlomo Y. Physiotherapy for Parkinson's disease: a comparison of techniques (Cochrane Review). In: *The Cochrane Library*, Issue 2. Oxford: Update Software, 2002.
103. American College of Sports Medicine: Position stand: the recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in health adults. *Med Sci Sports Exercise*. 1998;30(6):975-991.
104. Black JE, Isaacs KR, Andersson BJ, Alcantara AA, Greenough WT. Learning causes synaptogenesis, whereas motor activity causes angiogenesis, in cerebellar cortex of adult rats. *Proc Natl Acad Sci USA*. 1990;87:5568-5572.
105. Kleim JA, Hogg TM, VandenBerg PM, Cooper NR, Bruneau R, Remple M. Cortical synaptogenesis and motor map reorganization occur during late, but not early, phase of motor skill learning. *J Neurosci*. 2004;24:628-633.
106. Remple MS, Bruneau RM, VandenBerg PM, Goertzen C, Kleim JA. Sensitivity of cortical movement representations to motor experience: evidence that skill learning but not strength training induces cortical reorganization. *Behav Brain Res*. 2001;123:133-141.
107. Jones TA, Hawrylak N, Klintsova AY, Greenough

- WT. Brain damage, behavior, rehabilitation, recovery, and brain plasticity. *Ment Retard Dev Disabil Res Rev.* 1998;4:231-237.
108. Jones TA, Bury SD, Adkins-Muir DL, Luke LM, Allred RP, Sakata JT. Importance of behavioral manipulations and measures in rat models of brain damage and brain repair. *Ilar J.* 2003;44:144-152.
109. Johansson BB. Brain plasticity and stroke rehabilitation. The Willis Lecture. *Stroke.* 2000;31:373-377.
110. Lisman J, Spruston N. Postsynaptic depolarization requirements for LTP and LTD: a critique of spike timing-dependent plasticity. *Nat Neurosci.* 2005;8:839-841.
111. Peinemann A, Reimer B, Loer C, Quartarone A, Munchau A, Conrad B, Siebner HR. Long-lasting increase in corticospinal excitability after 1800 pulses of subthreshold 5 Hz repetitive TMS to the primary motor cortex. *Clin Neurophysiol.* 2004;115:1519-1526.
112. Taub E. Harnessing brain plasticity through behavioral techniques to produce new treatments in neurorehabilitation. *Am Psychol.* 2004;8:692-704.
113. Turner RS, Grafton ST, McIntosh AR, DeLong MR, Hoffman JM. The functional anatomy of parkinsonian Bradykinesia. *NeuroImage.* 2003a;19:163-179.
114. Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of Bradykinesia in Parkinson's disease. *Brain.* 2001;124:2131-2146.
115. Farley BG, Sherman S, Koshland GE. Shoulder muscle activity during multijoint movement in Parkinson's disease across a range of speeds. *Exp Brain Res.* 2003;154:160-175.
116. Pfann KD, Buchman AS, Comella CL, Corcos DM. Control of movement distance in Parkinson's disease. *Mov Disord.* 2001;16(6):1048-1065.
117. Desmurget M, Grafton ST, Vindras P, Grea H, Turner RS. The basal ganglia network mediates the planning of movement amplitude. *Eur J Neurosci.* 2004;19:2871-2880.
118. Morris M, Iansek R, Matyas T, Summers J. The pathogenesis of gait hypokinesia in Parkinson's disease. *Brain.* 1994;117:1169-1181.
119. Morris M, Iansek R, Matyas T, Summers J. Abnormalities in the stride length-cadence relation in Parkinsonian gait. *Mov Disord.* 1998;13:61-69.
120. Turner RS, Anderson ME. Pallidal discharge related to the kinematics of reaching movements in two dimensions. *J Neurophysiol.* 1997;77:1051-1074.
121. Turner RS, Grafton ST, Votaw JR, DeLong MR, Hoffman JM. Motor subcircuits mediating the control of movement velocity: a PET study. *J Neurophysiol.* 1998;80:2162-2176.
122. Nudo RJ, Milliken GW, Jenkins WM, Merzenich MM. Use-dependent alterations of movement representations in primary motor cortex of adult squirrel monkeys. *J Neurosci.* 1996;16:785-807.
123. Dancause N, Barbay S, Frost SB, et al. Extensive cortical rewiring after brain injury. *J Neurosci.* 2005;24(44):10167-10179.
124. Nudo RJ. Recovery after damage to motor cortical areas. *Curr Opin Neurobiol.* 1999;9(6): 740-747.
125. McFarland DH, Tremblay P. Clinical implications of cross-system interactions. *Semin Speech Lang.* 2006;27(4):300-309.
126. Ramig L, Sapir S, Countryman S, et al. Intensive voice treatment (LSVT) for individuals with Parkinson disease: a two-year follow-up. *J Neurol Neurosurg Psychiatry.* 2001;71:493-498.
127. El-Sharkawi A, Ramig L, Logemann J, et al. Swallowing and voice effects of Lee Silverman Voice Treatment: a pilot study. *J Neurol Neurosurg Psychiatry.* 2002;72(1):31-36.
128. Spielman J, Borod J, Ramig L. Effects of Intensive Voice Treatment (LSVT) on Facial Expressiveness in Parkinson's disease: preliminary data. *Cog Behav Neurol.* 2003;16(3):177-188.
129. Liotti M, Vogel D, Ramig L, et al. Hypophonia in Parkinson's disease: neural correlates of voice treatment revealed by PET. *Neurology.* 2003;60:432-440.
130. Narayana S, Vogel D, Brown S, et al. Mechanism of action of voice therapy in Parkinson's hypophonia—A PET study. A poster presented at the 11th Annual Meeting of the Organization for Human Brain Mapping; 2005; Toronto, Ontario, Canada.
131. Berardelli A, Dick JP, Rothwell JC, Day BL, Marsden CD. Scaling of the size of the first agonist EMG burst during rapid wrist movements in people with Parkinson's disease. *J Neurol Neurosurg Psychiatry.* 1986;49(11):1273-1279.
132. Demirci M, Grill S, McShane L, Hallett M. Impairment of kinaesthesia in Parkinson's disease. *Neurology.* 1995;45:A218.
133. Demirci M, Grill S, McShane L, Hallett M. A mismatch between kinesthetic and visual perception in Parkinson's disease. *Ann Neurol.* 1997;41:781-788.
134. Stelmach GE. Basal ganglia impairment and force control. In: J Requin, GE Stelmach, eds. *Tutorial in Motor Neuroscience.* Netherlands: Kluwer Academic Publishers; 1991:137-148.
135. Jobst E, Melnick M, Byl N, Dowling G, Aminoff M. Sensory perception in Parkinson's disease. *Arch Neurol.* 1997;54:450-454.
136. Klockgether T, Borutta M, Rapp H, Spiedler S, Dichgans J. A defect of kinaesthesia in Parkinson's disease. *Brain.* 1997;120:460-465.
137. Schneider J, Diamond S, Markham C. Deficits in orofacial sensorimotor function in Parkinson's disease. *Annals Neurol.* 1986;19:275-282.
138. Rickards C, Cody F. Proprioceptive control of wrist movements in Parkinson's disease. *Brain.* 1997;120:977-990.

139. Farley BG, Koshland GE Training BIG to move faster: The application of the speed-amplitude relation as a rehabilitation strategy for people with Parkinson's disease. *Exp Brain Res*. 2005;167(3):462-467.
140. Farley BE, Koshland GE Efficacy of a large-amplitude exercise approach for patients with Parkinson's disease—bradykinesia to balance. Presentation at: 9th International Congress of Parkinson's Disease and Movement Disorders, 2005; Abstract #466.
141. Fox C, Farley B, Ramig L, McFarland. An integrated speech and physical therapy approach for Parkinson disease: Training Big and Loud. Abstract for paper to be presented at the Biannual Conference on Motor Speech, Austin, Tex, 2006.
142. Fox CM, Farley BG. Learning Big and Loud™: an integrated rehabilitation approach to Parkinson' disease. Program No. 874.10, 2004 Abstract Viewer and Itinerary Planner. Washington, DC: Society for Neuroscience, Online.
143. Fox CM, Farley BG, Ramig, LO, McFarland D. An integrated rehabilitation approach to Parkinson's disease: Learning big and loud. *Mov Disord*. 2005;20(10):S127.
144. Adkins-Muir DL, Jones TA. Cortical electrical stimulation combined with rehabilitative training: enhanced functional recovery and dendritic plasticity following focal cortical ischemia in rats. *Neurol Res*. 2004;25:780-788.
145. Teskey GC, Flynn C, Goertzen CD, Monfils MH, Young NA. Cortical stimulation improves skilled forelimb use following a focal ischemic infarct in the rat. *Neurol Res*. 2003;25:794-800.
146. Ikeguchi M, Touge T, Nishiyama Y, Takeuchi H, Kuriyama S, Ohkawa M. Effects of successive repetitive transcranial magnetic stimulation on motor performances and brain perfusion in idiopathic Parkinson's disease *J Neurol Sci*. 2003;209:36-41.
147. Ramig L, Countryman S, Thompson L, Horii Y. A comparison of two forms of intensive speech treatment for Parkinson disease. *J Speech Hearing Res*. 1995;38:1232-1251.
148. Ramig L, Sapir S, Fox C, Countryman S. Changes in vocal intensity following intensive voice treatment (LSVT) in individuals with Parkinson disease: A comparison with untreated patients and normal age-matched controls. *Mov Disord*. 2001;16:79-83.
149. Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GE, Tanner CM. A responsive outcome for Parkinson's disease neuroprotection futility studies. *Ann Neurol*. 2005;57:197-203.
150. Farley BG, Derosa S, Koshland GE, Fox CM, Van Gemmert AWA. *Training Generalized Amplitude Across Motor Systems (BIG and LOUD™) Transfers to an Untrained Handwriting Task in Early Parkinson Disease*. Program No. 655.13. Atlanta, Ga: Society for Neuroscience; 2006.
151. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. *J Cereb Blood Flow Metab*. 2007;27(3):501-509.
152. Brizard M, Carcenac C, Bemelmans A, Feuerstein, Mallet J, Savasta M. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. *Neurobiol Dis*. 2006;1:90-101.
153. Jones TA, Chu CJ, Grande LA, Gregory AD. Motor skills training enhances lesion-induced structural plasticity in the motor cortex of adult rats. *J Neurosci*. 1999;19(22):10153-10163.
154. Comery TA, Shar R, Greenough WT. Differential rearing alters spine density on medium-sized spiny neurons in the rat corpus striatum: evidence for association of morphological plasticity with early response gene expression. *Neurobiol Learn Mem*. 1995;63:217-219.
155. Kleim JA, Lussnig E, Schwarz ER, Comery TA, Greenough WT. Synaptogenesis and Fos expression in the motor cortex of the adult rat after motor skill learning. *J Neurosci*. 1996;16:4529-4535.
156. Plautz EJ, Milliken GW, Nudo RJ. Effects of repetitive motor training on movement representations in adult squirrel monkeys: role of use versus learning. *Neurobiol Learn Mem*. 2000;74:27-55.
157. Ramig L, Pawlas A, Countryman S. *Lee Silverman Voice Treatment: A Practical Guide to Treating the Voice and Speech Disorders in Parkinson Disease*. Iowa City: National Center for Voice and Speech; 1995.
158. Brown RG, Marsden CD. Dual task performance and processing resources in normal subjects and patients with Parkinson's disease. *Brain*. 1991;114:215-231.
159. Robichaud JA, Pfann KD, Vaillancourt DE, Comella CL, Corcos DM. Force control and disease severity in Parkinson's disease. *Mov Disord*. 2005;20:441-450.
160. Pisani A, Centonze D, Bernardi G, Calabresi P. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. *Mov Disord*. 2005;20(4):395-402.
161. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. *Trends Neurosci*. 1990;13:266-271.
162. Graybiel AM. The basal ganglia and chunking of action repertoires. *Neurobiol Learn Mem*. 1998;70:119-136.
163. Satoh T, Nakai S, Sato T, Kimura M. Correlated coding of motivation and outcome of decision by dopamine neurons. *J Neurosci*. 2003;23:9913-9923.